Actual compliance to adjuvant chemotherapy in gastric cancer

Dong Wook Kim, Oh Kyoung Kwon, Moon Won Yoo, Seung Wan Ryu, Sung Jin Oh, Hoon Hur, Sun Hwi Hwang, Junhyun Lee, Sung Ho Jin, Sang Eok Lee, Jong Han Kim, Jin Jo Kim, In Ho Jeong, Ye Seob Jee

Research output: Contribution to journalArticle

Abstract

Purpose: This study aims to investigate the actual compliance with chemotherapy and analyze several factors affecting the compliance in patients with gastric cancer. Methods: From February 2012 to December 2014, we collected data of patients with gastric cancer who received adjuvant chemotherapy (TS-1 monotherapy or XELOX: capecitabine/oxaliplatin) in Korea. Results: We collected data of 1,089 patients from 31 institutions. The completion rate and dose reduction rate by age (≥60 years vs. <60 years) were 57.5% vs. 76.8% (P < 0.001) and 17.9% vs. 21.3% (P = 0.354); by body mass index (BMI) (≥23 kg/m 2 vs. <23 kg/m 2 ) were 70.2% vs. 63.2% (P = 0.019) and 19.2% vs. 19.9% (P = 0.987), respectively. The compliance by American Society of Anesthesiologists physical status (ASA PS) classification was as follows: completion rate was 74.4%, 62.8%, and 60% (P = 0.001) and the dose reduction rate was 18.4%, 20.7%, and 17.8% (P = 0.946) in ASA PS classification I, II, and III, respectively. The completion rate of TS-1 and XELOX was 65.9% vs. 70.3% (P = 0.206) and the dose reduction rate was 15.7% vs. 33.6% (P < 0.001). Furthermore, the completion rate of chemotherapy by surgical oncologists and medical oncologists was 69.5% vs. 63.2% (P = 0.028) and the dose reduction rate was 17.4% vs. 22.3% (P = 0.035), respectively. Conclusion: The compliance was lower in patients who were older than 60 years, had BMI <23 kg/m 2 , and had higher ASA PS classification. Furthermore, the patients showed higher compliance when they received chemotherapy from surgical oncologists rather than from medical oncologists.

Original languageEnglish
Pages (from-to)185-190
Number of pages6
JournalAnnals of Surgical Treatment and Research
Volume96
Issue number4
DOIs
Publication statusPublished - 2019 Apr 1

Fingerprint

Adjuvant Chemotherapy
Stomach Neoplasms
Compliance
oxaliplatin
Drug Therapy
Body Mass Index
Patient Compliance
Korea
Statistical Factor Analysis
Oncologists
titanium silicide
Anesthesiologists
XELOX

Keywords

  • Adjuvant chemotherapy
  • Advanced gastric cancer
  • Compliance

ASJC Scopus subject areas

  • Surgery

Cite this

Kim, D. W., Kwon, O. K., Yoo, M. W., Ryu, S. W., Oh, S. J., Hur, H., ... Jee, Y. S. (2019). Actual compliance to adjuvant chemotherapy in gastric cancer. Annals of Surgical Treatment and Research, 96(4), 185-190. https://doi.org/10.4174/astr.2019.96.4.185

Actual compliance to adjuvant chemotherapy in gastric cancer. / Kim, Dong Wook; Kwon, Oh Kyoung; Yoo, Moon Won; Ryu, Seung Wan; Oh, Sung Jin; Hur, Hoon; Hwang, Sun Hwi; Lee, Junhyun; Jin, Sung Ho; Lee, Sang Eok; Kim, Jong Han; Kim, Jin Jo; Jeong, In Ho; Jee, Ye Seob.

In: Annals of Surgical Treatment and Research, Vol. 96, No. 4, 01.04.2019, p. 185-190.

Research output: Contribution to journalArticle

Kim, DW, Kwon, OK, Yoo, MW, Ryu, SW, Oh, SJ, Hur, H, Hwang, SH, Lee, J, Jin, SH, Lee, SE, Kim, JH, Kim, JJ, Jeong, IH & Jee, YS 2019, 'Actual compliance to adjuvant chemotherapy in gastric cancer', Annals of Surgical Treatment and Research, vol. 96, no. 4, pp. 185-190. https://doi.org/10.4174/astr.2019.96.4.185
Kim, Dong Wook ; Kwon, Oh Kyoung ; Yoo, Moon Won ; Ryu, Seung Wan ; Oh, Sung Jin ; Hur, Hoon ; Hwang, Sun Hwi ; Lee, Junhyun ; Jin, Sung Ho ; Lee, Sang Eok ; Kim, Jong Han ; Kim, Jin Jo ; Jeong, In Ho ; Jee, Ye Seob. / Actual compliance to adjuvant chemotherapy in gastric cancer. In: Annals of Surgical Treatment and Research. 2019 ; Vol. 96, No. 4. pp. 185-190.
@article{9db8e3bd1295401aafa956e67b5bf98e,
title = "Actual compliance to adjuvant chemotherapy in gastric cancer",
abstract = "Purpose: This study aims to investigate the actual compliance with chemotherapy and analyze several factors affecting the compliance in patients with gastric cancer. Methods: From February 2012 to December 2014, we collected data of patients with gastric cancer who received adjuvant chemotherapy (TS-1 monotherapy or XELOX: capecitabine/oxaliplatin) in Korea. Results: We collected data of 1,089 patients from 31 institutions. The completion rate and dose reduction rate by age (≥60 years vs. <60 years) were 57.5{\%} vs. 76.8{\%} (P < 0.001) and 17.9{\%} vs. 21.3{\%} (P = 0.354); by body mass index (BMI) (≥23 kg/m 2 vs. <23 kg/m 2 ) were 70.2{\%} vs. 63.2{\%} (P = 0.019) and 19.2{\%} vs. 19.9{\%} (P = 0.987), respectively. The compliance by American Society of Anesthesiologists physical status (ASA PS) classification was as follows: completion rate was 74.4{\%}, 62.8{\%}, and 60{\%} (P = 0.001) and the dose reduction rate was 18.4{\%}, 20.7{\%}, and 17.8{\%} (P = 0.946) in ASA PS classification I, II, and III, respectively. The completion rate of TS-1 and XELOX was 65.9{\%} vs. 70.3{\%} (P = 0.206) and the dose reduction rate was 15.7{\%} vs. 33.6{\%} (P < 0.001). Furthermore, the completion rate of chemotherapy by surgical oncologists and medical oncologists was 69.5{\%} vs. 63.2{\%} (P = 0.028) and the dose reduction rate was 17.4{\%} vs. 22.3{\%} (P = 0.035), respectively. Conclusion: The compliance was lower in patients who were older than 60 years, had BMI <23 kg/m 2 , and had higher ASA PS classification. Furthermore, the patients showed higher compliance when they received chemotherapy from surgical oncologists rather than from medical oncologists.",
keywords = "Adjuvant chemotherapy, Advanced gastric cancer, Compliance",
author = "Kim, {Dong Wook} and Kwon, {Oh Kyoung} and Yoo, {Moon Won} and Ryu, {Seung Wan} and Oh, {Sung Jin} and Hoon Hur and Hwang, {Sun Hwi} and Junhyun Lee and Jin, {Sung Ho} and Lee, {Sang Eok} and Kim, {Jong Han} and Kim, {Jin Jo} and Jeong, {In Ho} and Jee, {Ye Seob}",
year = "2019",
month = "4",
day = "1",
doi = "10.4174/astr.2019.96.4.185",
language = "English",
volume = "96",
pages = "185--190",
journal = "Annals of Surgical Treatment and Research",
issn = "2288-6575",
publisher = "Korean Surgical Society",
number = "4",

}

TY - JOUR

T1 - Actual compliance to adjuvant chemotherapy in gastric cancer

AU - Kim, Dong Wook

AU - Kwon, Oh Kyoung

AU - Yoo, Moon Won

AU - Ryu, Seung Wan

AU - Oh, Sung Jin

AU - Hur, Hoon

AU - Hwang, Sun Hwi

AU - Lee, Junhyun

AU - Jin, Sung Ho

AU - Lee, Sang Eok

AU - Kim, Jong Han

AU - Kim, Jin Jo

AU - Jeong, In Ho

AU - Jee, Ye Seob

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Purpose: This study aims to investigate the actual compliance with chemotherapy and analyze several factors affecting the compliance in patients with gastric cancer. Methods: From February 2012 to December 2014, we collected data of patients with gastric cancer who received adjuvant chemotherapy (TS-1 monotherapy or XELOX: capecitabine/oxaliplatin) in Korea. Results: We collected data of 1,089 patients from 31 institutions. The completion rate and dose reduction rate by age (≥60 years vs. <60 years) were 57.5% vs. 76.8% (P < 0.001) and 17.9% vs. 21.3% (P = 0.354); by body mass index (BMI) (≥23 kg/m 2 vs. <23 kg/m 2 ) were 70.2% vs. 63.2% (P = 0.019) and 19.2% vs. 19.9% (P = 0.987), respectively. The compliance by American Society of Anesthesiologists physical status (ASA PS) classification was as follows: completion rate was 74.4%, 62.8%, and 60% (P = 0.001) and the dose reduction rate was 18.4%, 20.7%, and 17.8% (P = 0.946) in ASA PS classification I, II, and III, respectively. The completion rate of TS-1 and XELOX was 65.9% vs. 70.3% (P = 0.206) and the dose reduction rate was 15.7% vs. 33.6% (P < 0.001). Furthermore, the completion rate of chemotherapy by surgical oncologists and medical oncologists was 69.5% vs. 63.2% (P = 0.028) and the dose reduction rate was 17.4% vs. 22.3% (P = 0.035), respectively. Conclusion: The compliance was lower in patients who were older than 60 years, had BMI <23 kg/m 2 , and had higher ASA PS classification. Furthermore, the patients showed higher compliance when they received chemotherapy from surgical oncologists rather than from medical oncologists.

AB - Purpose: This study aims to investigate the actual compliance with chemotherapy and analyze several factors affecting the compliance in patients with gastric cancer. Methods: From February 2012 to December 2014, we collected data of patients with gastric cancer who received adjuvant chemotherapy (TS-1 monotherapy or XELOX: capecitabine/oxaliplatin) in Korea. Results: We collected data of 1,089 patients from 31 institutions. The completion rate and dose reduction rate by age (≥60 years vs. <60 years) were 57.5% vs. 76.8% (P < 0.001) and 17.9% vs. 21.3% (P = 0.354); by body mass index (BMI) (≥23 kg/m 2 vs. <23 kg/m 2 ) were 70.2% vs. 63.2% (P = 0.019) and 19.2% vs. 19.9% (P = 0.987), respectively. The compliance by American Society of Anesthesiologists physical status (ASA PS) classification was as follows: completion rate was 74.4%, 62.8%, and 60% (P = 0.001) and the dose reduction rate was 18.4%, 20.7%, and 17.8% (P = 0.946) in ASA PS classification I, II, and III, respectively. The completion rate of TS-1 and XELOX was 65.9% vs. 70.3% (P = 0.206) and the dose reduction rate was 15.7% vs. 33.6% (P < 0.001). Furthermore, the completion rate of chemotherapy by surgical oncologists and medical oncologists was 69.5% vs. 63.2% (P = 0.028) and the dose reduction rate was 17.4% vs. 22.3% (P = 0.035), respectively. Conclusion: The compliance was lower in patients who were older than 60 years, had BMI <23 kg/m 2 , and had higher ASA PS classification. Furthermore, the patients showed higher compliance when they received chemotherapy from surgical oncologists rather than from medical oncologists.

KW - Adjuvant chemotherapy

KW - Advanced gastric cancer

KW - Compliance

UR - http://www.scopus.com/inward/record.url?scp=85063880727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063880727&partnerID=8YFLogxK

U2 - 10.4174/astr.2019.96.4.185

DO - 10.4174/astr.2019.96.4.185

M3 - Article

VL - 96

SP - 185

EP - 190

JO - Annals of Surgical Treatment and Research

JF - Annals of Surgical Treatment and Research

SN - 2288-6575

IS - 4

ER -